About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Pirtobrutinib in R/R CLL
By
Alvaro Alencar
383 views
January 10, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Related Content
AUTOPLAY
ON
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
06:56
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…
Feat.
M. Shadman
15:21
5th SOHO Italy Annual Conference
How I Treat CLL at the MD Anderson Cancer Center
Feat.
A. Ferrajoli
06:59
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…
10:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…
Feat.
J. Woyach
08:45
Insights from 2023 ASH Annual Meeting
The Best of CLL: Highlights & Key Takeaways
Feat.
V. Yazbeck
06:34
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…
Feat.
A. Kittai
18:01
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…
Feat.
J. Rhodes
06:21
City of Hope
Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL
Feat.
A. Danilov
06:28
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…
Feat.
O. Al-Sawaf
05:12
Insights from 2023 ASH Annual Meeting
R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…
Feat.
N. Shah
11:39
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…
Feat.
G. Gaidano
20:58
Andrew Lipsky
CLL: Recent Updates on the Use of BTK Inhibitors
22:47
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the…
Feat.
J. Woyach
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…